European Companies Search Engine
EU funding (€3,852,127): Regulation of red cell life-span, erythropoiesis, survival, senescence and clearance Hor11 Aug 2015 EU Research and Innovation programme "Horizon"
Overview
Text
Regulation of red cell life-span, erythropoiesis, survival, senescence and clearance
Anaemia is the most common pathological condition affecting 1.6 billion individuals worldwide. It thus presents a serious health care problem and an economic burden. Reduction in red blood cell (RBC) number can be caused by blood loss, diet, stress conditions including endurance sport, and pathologies which are caused by primary genetic aberrations or are secondary to the malfunction of other cell types. Transfusion of RBC, which is often the only cure for severe cases of anaemia, is associated with risks such as thrombosis and transfusion reactions due to allo-immunisation. There is an unmet need to improve treatment of anaemia through early and accurate diagnosis, targeted treatment, and increased safety and effectiveness of RBC transfusion. The aim of RELEVANCE is to improve fast and cost-effective diagnosis of the underlying cause of primary anaemia, and to improve treatment options for both general and personalised medicine. We defined five key objectives: (1) to improve diagnostics of anaemia, particularly for hereditary rare forms of anaemia (RA); (2) to find novel treatments for anaemia that target RBC production, ageing and clearance; (3) to reduce premature loss of RBC following transfusion; (4) to produce cultured RBC for transfusion; (5) to monitor and optimise RBC function during sport and exercise. RELEVANCE will train 15 early stage researchers (ESR) at four SMEs and eight academic partners, two of whom are at blood supply centres and two are diagnostic centres for RA. The continuous interactions between the clinic, blood supply centers, basic research, and industry will select for the most relevant unmet medical needs, and will stimulate innovative procedures that are immediately probed for applicability and validity both in a research and a clinical setting. RELEVANCE will organize three open access summer schools, extending training beyond the ESR of the ITN sustaining the critical number of young talented professionals in the field.
Funded Companies:
| Company name | Funding amount |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH | ? |
| ARIVIS AG | €249,216 |
| Centre National de la Recherche Scientifique Cnrs | €262,876 |
| Epigem Ltd. | €273,288 |
| Fundacio Institut de Recerca Contra La Leucemia Josep Carreras | €238,440 |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | €9,432.94 |
| Institut National de la Sante et de la Recherche Medicale | €262,876 |
| NANION TECHNOLOGIES GmbH | €249,216 |
| Optorobotix ApS | €201,446 |
| Stichting |
€510,749 |
| UNIVERSITAT DES SAARLANDES | €498,433 |
| €309,431 | |
| Universita Degli Studi DI Pavia | €258,061 |
| Universitair Medisch Centrum Utrecht | €255,374 |
| €273,288 |
Source: https://cordis.europa.eu/project/id/675115
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: EURICE European Research and Project Office GmbH, St. Ingbert, Germany.
The visualizations for "EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH - EU funding (€3,852,127): Regulation of red cell life-span, erythropoiesis, survival, senescence and clearance"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
